Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion
Written by Emily J. Thompson, Senior Investment Analyst
Source: Benzinga
Impact of Trump's Executive Order: Donald Trump's recent executive order aimed at reducing drug prices is expected to significantly affect pharmacy benefit managers (PBMs), which may face scrutiny over their pricing practices, while pharmaceutical manufacturers could experience compressed margins due to increased pressure to lower prices.
Calls for Transparency: The order emphasizes the need for transparency in PBM fees and operations, with notable figures like Mark Cuban criticizing PBMs for controlling rebate negotiations and contributing to healthcare spending inefficiencies.
Analyst Views on PPH
Wall Street analysts forecast PPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PPH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 106.420
Low
Averages
High
Current: 106.420
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
